Literature DB >> 1676623

Ethnicity and psychotropic drugs.

W S Bond1.   

Abstract

The literature concerning the effect of race and ethnicity on the pharmacokinetics of psychotropic drugs is reviewed, and recommendations concerning the use of these agents are presented. While no differences in the pharmacokinetics of dosage requirements of antipsychotic drugs have been demonstrated among black, Hispanic, and white persons, Asians seem to have a lower threshold for both the therapeutic and adverse effects of antipsychotic drugs than do Caucasians. Use of lower than usual initial dosages of antipsychotic drugs in Asian patients appears to be prudent. Although ethnicity may have an effect on antidepressant drug pharmacology and dosage requirements, the available data are not sufficiently convincing to make any dosage recommendations. Claims that Asians require lower dosages of lithium than do other ethnic groups are not supported by the available evidence. Higher plasma benzodiazepine concentrations and lower drug clearance observed in Asians compared with Caucasians are consistent with clinical observations of lower dosage requirements for Asian patients; smaller than usual dosages of these agents are recommended for Asian patients. Interracial pharmacokinetic and pharmacodynamic differences for psychotropic drugs can affect clinical outcomes. Further study of this issue is warranted.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1676623

Source DB:  PubMed          Journal:  Clin Pharm        ISSN: 0278-2677


  3 in total

Review 1.  Clinical trials and transethnic pharmacology.

Authors:  M E Kitler
Journal:  Drug Saf       Date:  1994-11       Impact factor: 5.606

2.  Comparison of aminoglycoside pharmacokinetics in Asian, Hispanic, and Caucasian patients by using population pharmacokinetic methods.

Authors:  S S Jhee; J P Burm; M A Gill
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

3.  Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia.

Authors:  Jonathan M Meyer; Yongcai Mao; Andrei Pikalov; Josephine Cucchiaro; Antony Loebel
Journal:  Int Clin Psychopharmacol       Date:  2015-11       Impact factor: 1.659

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.